Sunday O. Akintoye
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sunday O. Akintoye has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Derek Stefanik
Department of Oral Medicine, University of Pennsylvania School of Dental Medicine, Philadelphia PA
3 shared publicationsMichael T. Collins
Craniofacial and Skeletal Diseases Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda MD 20892, USA
3 shared publicationsMonika Damek-Poprawa
Department of Microbiology, School of Dental Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
3 shared publications- Pamela Gehron Robey
Skeletal Biology Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
2 shared publications - A.I. Chou
Department of Bioengineering, University of Pennsylvania, 240 Skirkanich Hall, 210 South 33rd Street, Philadelphia, PA 19104-6321, USA
1 shared publication - Aleksandra Wojtowicz
Faculty of Biology and Earth Sciences, Department of Cytology & Histology, Jagiellonian University, Krakow, Poland
1 shared publication
Latest Publications
- 1 July 2022
- Vol. 53 (7) , 616-623
Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature
Objective:The objective of this systematic review was to evaluate the risks of medication-related osteonecrosis of the jaw (MRONJ) in fibrous dysplasia (FD) and McCune-Albright syndrome (MAS) patients treated with bisphosphonates. Method and materials: A systematic review of the literature was performed by searching PubMed and Embase databases using MeSH terms (fibrous dysplasia of bone, "fibrous dysplasia, polyostotic, " osteonecrosis, jaw, therapeutics, diphosphonates, denosumab, teriparatide, estrogens, hormones, raloxifene hydrochloride, calcitonin, cathepsin K) and non-MeSH terms (antiresorptive therapy, antiresorptives, bisphosphonate, estrogen therapy, hormone therapy, bazedoxifene, cathepsin K inhibitor). Articles were limited to human studies, in English language, in which patients were on antiresorptives for at least 1 year. PRISMA statement guidelines were used to eliminate non-relevant studies. The PICOT question asked was, "Does exposure to bisphosphonates and other antiresorptives cause occurrence of MRONJ in fibrous dysplasia and fibrous dysplasia/McCune-Albright syndrome patients followed up for at least 1 year? " Results: Eight eligible articles were included in the quantitative synthesis after articles were screened using a PRISMA flowchart. There were 12 reported occurrences of MRONJ among a combined total of 312 fibrous dysplasia and fibrous dysplasia/McCune-Albright syndrome patients (3.85%). Conclusion: Patients with fibrous dysplasia or fibrous dysplasia/McCune-Albright syndrome have a low incidence of MRONJ and may ap parently have low susceptibility to spontaneous development of MRONJ.
- 1 July 2022
- Vol. 53 (7) , 616-623
Risk of developing spontaneous MRONJ in fibrous dysplasia patients treated with bisphosphonates: a systematic review of the literature
Objective:The objective of this systematic review was to evaluate the risks of medication-related osteonecrosis of the jaw (MRONJ) in fibrous dysplasia (FD) and McCune-Albright syndrome (MAS) patients treated with bisphosphonates. Method and materials: A systematic review of the literature was performed by searching PubMed and Embase databases using MeSH terms (fibrous dysplasia of bone, "fibrous dysplasia, polyostotic, " osteonecrosis, jaw, therapeutics, diphosphonates, denosumab, teriparatide, estrogens, hormones, raloxifene hydrochloride, calcitonin, cathepsin K) and non-MeSH terms (antiresorptive therapy, antiresorptives, bisphosphonate, estrogen therapy, hormone therapy, bazedoxifene, cathepsin K inhibitor). Articles were limited to human studies, in English language, in which patients were on antiresorptives for at least 1 year. PRISMA statement guidelines were used to eliminate non-relevant studies. The PICOT question asked was, "Does exposure to bisphosphonates and other antiresorptives cause occurrence of MRONJ in fibrous dysplasia and fibrous dysplasia/McCune-Albright syndrome patients followed up for at least 1 year? " Results: Eight eligible articles were included in the quantitative synthesis after articles were screened using a PRISMA flowchart. There were 12 reported occurrences of MRONJ among a combined total of 312 fibrous dysplasia and fibrous dysplasia/McCune-Albright syndrome patients (3.85%). Conclusion: Patients with fibrous dysplasia or fibrous dysplasia/McCune-Albright syndrome have a low incidence of MRONJ and may ap parently have low susceptibility to spontaneous development of MRONJ.
- Open Access
- 1 January 2016
- Published by Elsevier in Dental Clinics of North America
- Vol. 60 (1) , 265-277
Chemical and Radiation-Associated Jaw Lesions
- 1 January 2016
- Published by Elsevier in Dental Clinics of North America
- Vol. 60 (1) , 265-277
Open AccessChemical and Radiation-Associated Jaw Lesions
- Top Cited Papers
- 1 April 2014
- Published by Elsevier in Dental Clinics of North America
- Vol. 58 (2) , 281-297
Recurrent Aphthous Stomatitis
- 1 April 2014
- Published by Elsevier in Dental Clinics of North America
- Vol. 58 (2) , 281-297
Top Cited PapersRecurrent Aphthous Stomatitis
- Open Access
- 1 September 2013
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 116 (3) , e149-e155
Dental perspectives in fibrous dysplasia and McCune–Albright syndrome
- 1 September 2013
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 116 (3) , e149-e155
Open AccessDental perspectives in fibrous dysplasia and McCune–Albright syndrome
- 1 March 2013
- Vol. 44 (3) , 267-279
Review of the complications associated with treatment of oropharyngeal cancer: A guide for the dental practitioner
Oropharyngeal cancer (OPC) is the sixth most common cancer worldwide. Focus on risk factors, improved diagnostic methods and effective management strategies have made it possible to successfully treat OPC. However, the 5-year survival rate has not improved for several years due to multiple treatment complications, tissue morbidity, loss of function, and diminished quality of life. Survivors are faced with complications like oral mucositis, hyposalivation, osteoradionecrosis, tissue fibrosis, morbidity from jaw resection, disfigurement, and loss of function that further diminish quality of life. The aim of this review is to highlight major complications associated with treatment of OPC via a literature search and review of available options for identification and management of these complications. Relevant publications on oral complications of OPC therapy were thoroughly reviewed from the literature published between the years 1988 and 2012. We evaluated reported incidence, prevalence, and risk factors for oral complications of chemotherapy and radiotherapy for OPC. The authors conducted an electronic search using English language databases, namely PubMed Plus, Medline (Pre-Medline and Medline), Cochrane Database of Systematic Reviews (evidence-based medicine), Dentistry & Oral Sciences Source, A ccessScience, Embase, Evidence-Based Medicine Reviews Multifile, Google Scholar, ISI Journal Citation Reports, and Ovid Multi-Database. We identified the most common complications associated with the treatment of oral cancers. Based on the information gathered, there is evidence that survival of OPC extends beyond eradication of the diseased tissue. Understanding the potential treatment complications and utilizing available resources to prevent and minimize them are important. Caring for OPC survivors should be a multidisciplinary team approach involving the dentist, oncologist, internist, and social worker to improve the currently stagnant 5-year survival rate of OPC. More emphasis on improved quality of life after elimination of the cancer will ultimately improve OPC survivorship.
- 1 March 2013
- Vol. 44 (3) , 267-279
Review of the complications associated with treatment of oropharyngeal cancer: A guide for the dental practitioner
Oropharyngeal cancer (OPC) is the sixth most common cancer worldwide. Focus on risk factors, improved diagnostic methods and effective management strategies have made it possible to successfully treat OPC. However, the 5-year survival rate has not improved for several years due to multiple treatment complications, tissue morbidity, loss of function, and diminished quality of life. Survivors are faced with complications like oral mucositis, hyposalivation, osteoradionecrosis, tissue fibrosis, morbidity from jaw resection, disfigurement, and loss of function that further diminish quality of life. The aim of this review is to highlight major complications associated with treatment of OPC via a literature search and review of available options for identification and management of these complications. Relevant publications on oral complications of OPC therapy were thoroughly reviewed from the literature published between the years 1988 and 2012. We evaluated reported incidence, prevalence, and risk factors for oral complications of chemotherapy and radiotherapy for OPC. The authors conducted an electronic search using English language databases, namely PubMed Plus, Medline (Pre-Medline and Medline), Cochrane Database of Systematic Reviews (evidence-based medicine), Dentistry & Oral Sciences Source, A ccessScience, Embase, Evidence-Based Medicine Reviews Multifile, Google Scholar, ISI Journal Citation Reports, and Ovid Multi-Database. We identified the most common complications associated with the treatment of oral cancers. Based on the information gathered, there is evidence that survival of OPC extends beyond eradication of the diseased tissue. Understanding the potential treatment complications and utilizing available resources to prevent and minimize them are important. Caring for OPC survivors should be a multidisciplinary team approach involving the dentist, oncologist, internist, and social worker to improve the currently stagnant 5-year survival rate of OPC. More emphasis on improved quality of life after elimination of the cancer will ultimately improve OPC survivorship.
- Open Access
- 1 February 2013
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 115 (2) , 201-211
Onset of mandible and tibia osteoradionecrosis: a comparative pilot study in the rat
- 1 February 2013
- Published by Elsevier in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
- Vol. 115 (2) , 201-211
Open AccessOnset of mandible and tibia osteoradionecrosis: a comparative pilot study in the rat
- 1 December 2012
- Published by Elsevier in Journal of Evidence-Based Dental Practice
- Vol. 12 (4) , 228-230
Dental Implant Failure in Middle-Aged Women may be Associated With Positive History of Oral Bisphosphonate Treatment
- 1 December 2012
- Published by Elsevier in Journal of Evidence-Based Dental Practice
- Vol. 12 (4) , 228-230
Dental Implant Failure in Middle-Aged Women may be Associated With Positive History of Oral Bisphosphonate Treatment
- 1 September 2012
- Published by Elsevier in Journal of Evidence-Based Dental Practice
- Vol. 12 (3) , 251-253
Risks for Jaw Osteonecrosis Drastically Increases After 2 Years of Bisphosphonate Therapy
- 1 September 2012
- Published by Elsevier in Journal of Evidence-Based Dental Practice
- Vol. 12 (3) , 251-253
Risks for Jaw Osteonecrosis Drastically Increases After 2 Years of Bisphosphonate Therapy
- 1 June 2012
- Published by Elsevier in Journal of Evidence-Based Dental Practice
- Vol. 12 (2) , 116-118
Risks for Jaw Osteonecrosis Drastically Increases After 2 Years of Bisphosphonate Therapy
- 1 June 2012
- Published by Elsevier in Journal of Evidence-Based Dental Practice
- Vol. 12 (2) , 116-118
Risks for Jaw Osteonecrosis Drastically Increases After 2 Years of Bisphosphonate Therapy
- 1 May 2010
- Published by Elsevier in Archives of Oral Biology
- Vol. 55 (5) , 358-364
Human bone marrow stromal cells display variable anatomic site-dependent response and recovery from irradiation
- 1 May 2010
- Published by Elsevier in Archives of Oral Biology
- Vol. 55 (5) , 358-364
Human bone marrow stromal cells display variable anatomic site-dependent response and recovery from irradiation